Professional Documents
Culture Documents
Zeki Altun
$EVWUDFW
06
6
6+
+.
-+
0.+
0
*
0+.4+4+
7
+6
4
8
+
+0
+.
++0
7+.
06
6
6+
0
+*
7+
-
+6+
.+0+
+
#
+6
7+
+
0+
06
6
6+
0
7#+76
4
8
.+06
6
6+
-
+
+
#
+8
+0+769/:
7+0+769;/:-
+6
+
<+
6
7
915:
4+#6
<+
951:
8
0
=
-
.+0
15
66+<0
!07+.+-
0
+77
7
9!#
>:6706
6
6+
6
+
6
-
1+
+.
8
4+
-
0
+
+.+
0
6006
715+
#
4/
00
6
+0
9#:15+
+
+06
4.
+0
#6+.
06
+++
0
+
+.6006
0
67+.+-
+-
.+-+!
<+
-
.+
4
.
0+.4+4+
06
6
6+
+76*+
+6+-
66
64
6
467+.6++6+0
0+
+06
+-
4
+
+
4%'#4
6
/##2
++
0
60
4
06
4
0+
-
%'#6
4
4+0
/
&
*5
&
/
/$
/!$
/
/1/
,
1;,
1
;/
;
,
@
/
1
15
?C
#
5,
A
A5#/
&1
5,1
51
51
A
D
+
=+-+-+
+
*6+6
&
1
?
?
/
,
6
/61
++0+76
,
+<-+
1
;+,0
1
+6+
=+
;/+0+76
;
,0
A
+
B+
8/+0+76
8#81<+
+1<+
5
7
+
6
+0
*
06
+0
5+0
+<
A-+
A
#5
8/+0+76
&+-
1<+
+#5
,
01<+
+#5
1<+
+#5
+
<+
A
+
+
+
7
A
+
*0
A
+
*0
A
D+
/LVWRI3DSHUV
3DSHU,
0LFURH[WUDFWLRQLQ3DFNHG6\ULQJH0(36IRU/LTXLGDQG*DV
&KURPDWRJUDSK\$SSOLFDWLRQV3DUW,,'HWHUPLQDWLRQRI5RSLYDFDLQH
DQGLWV0HWDEROLWHVLQ+XPDQ3ODVPD6DPSOHV8VLQJ0(36ZLWK/LTXLG
&KURPDWRJUDSK\7DQGHP0DVV6SHFWURPHWU\
+0
-
#A
0
;&+0-
7"%
9:!$$#!%"
3DSHU,,
1HZ7UHQGVLQ6DPSOH3UHSDUDWLRQ2QOLQH0LFURH[WUDFWLRQLQ3DFNHG
6\ULQJH0(36IRU/&DQG*&$SSOLFDWLRQV3DUW,,,'HWHUPLQDWLRQ
DQG9DOLGDWLRQRI/RFDO$QDHVWKHWLFVLQ+XPDQ3ODVPD6DPSOHV8VLQJD
&DWLRQH[FKDQJH6RUEHQWDQG0(36/&0606
+0
-
#A
0
;&+0-
7
$!"9:!%#!"
3DSHU,,,
,QFUHDVLQJ6DPSOH3UHSDUDWLRQ7KURXJKSXW8VLQJ0RQROLWKLF
0HWKDFU\ODWH3RO\PHUDV3DFNLQJ0DWHULDOIRU7LSV0LQXWHVSHU
:HOO3ODWH
;&+0-
7
+0
-
#A
0-0
+
9:
,#
!
++
(
!!06
5
6+
(
!!!+#5
1<+
951: (
!!!!06
5+
7
51$
!!!/+06+
A
+
51 %
!*
06
5
6+
!
!"+
<+
5
7
915: !!
!
&
5++5+0
+
+!
!8/+0+769/: !
!'6
+0
9:!"
!(06
!
!(!+
!
!(A++
?+0+
!'
*
0+.*2+!(
"A
,+
!$
"!15/+
+
!$
"
+,
+60
956
:!$
"!*
+-
!%
"*
2
7+
""*
1+
+
"
""/#+
"C706
*+76
7+
+5
*6956
:
"!*
5
6+
+.5++5+0
+
+
"
+.5+9;#1;,#&:+
+.+56
*6
"06
7 '
"'
(
/+
+
%
+4
7
0
"
A
.
"!
,QWURGXFWLRQ
6DPSOH3UHSDUDWLRQ
4
+.
6
+06
<0
+..+
<06
+
0
+-++7+7
06
+-
.+
++
+
0
*
06
6
6+
-
+0
06+
6
6+
06
6
6+
+.
6
8
+
.+006
+.+0-
.+
*
.
6+
-
+
0+
8
4-
+06
*6+
0-
7
6+-
4+
66
-
++.
06
6
6+
0
++
+
0
00
0-
+.
4+
7
6-
+
-
+
0
.
-
+
+0
E!FB
0-
+.06
7+47#+76
.
+0
8
-
+0
8
/+00+
06
6
6+
0
+
8#8
<+
91:+#6
<+
951:
+#6
0+
<+
951:
6ROLG3KDVH([WUDFWLRQ63(
8#+
<+
++.
+#6
<+
951:
0
+
.++
+
++
+.7
7+
66+51+
0++00+
06
6
6+
0
+
0
+.
0
7
+
0
60
66+
EF514
+6
+06
0
+
6
0
.+
1+0
6+-
0
+1
-+
..+
+0
+
0
7
+0
+.7#6+
E#F
*
.
66+
+.51
+
-
+.0
+4
7
!%EF
7
+
6
4!#!7+.7
-+
&
+
+7
0
06
<4
6
+
?+A
E'F*
46
.+0
.+
0
+
+.
+
++
4
+60
+.51+
4
4.+0
46
4
..
0
E"F*
7
.+0
+
0+6+6
.+0EF6+
+
+.
7
+4
B7
!
Figure 1. Schematic diagram showing a typical SPE cartridge.
*
+
+.
+6
7
-
+
7+-
6
-
4
.517
-
=
+
7.+0"07+!
7+.+-
4
!07+07+-
7
0+4
*
0++00+
6
70
#-
4
0
-+
0
7+#
6+0
#
-
=
6+0
B
+
0
+.0
0+
..
517
+
+
.+
+-
+-
6
+.
+48
6$6$6$6"#
6+#6
<+
+
.+6+
7
6B7
.
6
+-
+
+
4"#-
+0
+.+
+
0+
06
6+-
+
+.
*
+
666+
+.
06
++
+7
<+
*
6.++4
-
7
7+.
+-
.+0
.
4++
7
B
+.
.+0
+-
7+
7+
E(F
*
60
-
7
6+
7
6
51
+
7+
+
6
6
+.8+0+769/:E"(F
&RPSRXQGV5HWHQWLRQLQ63(
51
6+
-
+
-+
+.
-
4
+6
70
80+-
6
*
..
51
.+
+.
-
+
6
+.-+
66
<+
EF*
+0
7
#6
51
C
+
6
6
4
0-+
.
+
7+6+
+
.
/!$+0
-/$
+
<
*
6
70
/9
!:
51
-
0
<
6
6
7
51++7
+
4
.+4+7
+-
-7-.+8
+
+
+06
70+00+
06+
*
+
+.
+
+
+-
60++6+-
+
*+
.+0
+-
+
#6++
B+
7
4
++
+
<
7
51
-
*
+
0
060-
+
++
-
4
7
7
.
+
7+6+
.
+.
+-
*+
+.
++
76C
=
.
+
7+6+.
+-
+
=
7
+
+
47+
7
+
+06+
6$4,
"#
A
06
6
6+
.++
+4+0
=
6+
06
+76
+-
+
#
+6
06
6
6+
+
+
0E(#!F
*
.
06+0
=
6+
6+
706
+764
+
4
++
+.
4.+051
E!!F66
6E!!#!F+0
4
7
0E!"#!'F
0#4
6
E!(FB
0
=+
+60
+.
4
0+
<+
8
+0
<06
+.
0
7
7
4
8
4-
7
+#6
0+
<+
951:6
0++00+
0+
<+
8
E!$#!F
51.
#.-
+
+
+
4
66+6
+
6
.+06
72
+
6
6
+
4
06
0<6+
7+.
-
4
6
6
*
.-
6
+.
;/
G
+.+
+-+
*
<+
..
+.51
6
+
0-
+..+
<+
0
7+
06
6C
+
+
06
51
-
<+
6
#
+
+
+.
.+07
+8
+06
+#6
0
<+
95,1:
8
4=
+.77
7
.+06
7E#"F*
4+.
10
0LFURH[WUDFWLRQLQ3DFNHG6\ULQJH0(36
+
<+
6
7
915:
406
6
6+
8
77
7
<+
E'#(F
15
+-
0
-+!07
+
7
-
67
46+
.
+
-+
+-
4
7
-
Figure 3. Schematic picture of microextraction in packed syringe (MEPS).
*
06
6+
7
6
15
0++
+.51&
.
+
+
7+.
+-
4
66+6
+
9:
06
++
4
+7
+
7
6
+4
+
+
0
*.++4
-4
7
6+
0+
.
.
+.
<
+
/+;/
G
+
15
-
+
+
#
+/+;/4+
0+.+
+.
0
0
+
-
.+0
15
+-
0
-
6
7-
++
7
/+06
+-+
0
+
0+
<
+
8
4
5,
+-
0++.
15-7
7
-
-
44
7
+.-
+-
11
12
*
06
+
+
+6+.
+0
-
G
+*
6069:
.+4+.0+-
6
+7
+0
*
0+
4..
+7
+0
+
.
+
.+0
+0
*
7
4
07
6
+
.+
+.0
6
+
6
+
..
+.
+
+
6
*
+
<6
-
+
.+@
k =
t r t0
t0
9!:
4
+
0
.+
+
0
.+
0DVV6SHFWURPHWU\06
6
+0
9:4+
-
6JJ*+0+
9!$'#
!%:E"F++
+.
0+06+
0
.+
0+
*
-
0
6++
+.+
6+
+.+
+
7+
0#+#7
90K=:+
0E"'FB+006
08
4
8
.+0+
-
+-
/+0-
7/
0
44+
L
07
M
E"(F/+6
+
6
4
+6
0
&
+...
0-
4
7
7
4+
0
+
+0
7
+
0+
0-
6+
7
0-
.
+
76
*
+
=+
8
4
+6+
=+
91:
+6
6+
+
0+
*
+
.+0
/46
+
7
6-
+
+.46+
6+
9"#D:466
*
.
++
+-
6+=
+6+..
+6
*+
77
+7
9 :.+4
+
7
6+
6&
.+
7
06
+0
6+-
13
Figure 5. Schematic presentation of how SRM ion experiments in MS-MS are carried out.
6$;"#
6$;$6 #
!
A+6
+
-6
-0
6
+
7
B7
'A+6
-6
0
.+7
.+6++6
6
.EF
-6
4
00<
+6
<
#9#:#
+0
A+6
+4
+
++<6+
-6
E!F
+
0
..
0
+.
+
EF
14
A+6
0
-+=
-
.+
-
7
<
0
EF*
0
-+64
+0+<+
#
+
E"F
*
0G+0
-+
+.+6
55O
"#?C#+6
B7
'
CH3 O
H
N
N
H
C3H7
CH3 O
CH3 O
N
H
N
H
C3H7
C3D7
CH3
CH3
3-OH-ropivacaine, Mw 290 g/mol
N
H
CH3
Lidocaine, Mw 234 g/mol
2H -ropivacaine,
7
CH3 O
N
CH3
CH3
HO
CH3 O
Mw 281 g/mol
CH3 O
C2H5
C2H5
C4H9
CH3
Bupivacaine, Mw 288 g/mol
Figure 6. Structures and molecular weights of local anaesthetics utilized in this work.
15
6$;$4'
/#"
A++
++0+
B7
(
6
+
6+-
4
#
7E#F*
7
-
#
6
9/:4
=0
6+
7+
6+
*
..
+.
7
-+
+.
6+.
+
+
+., .70
+
-+
+.A
,
#6
+
+.
6+6+
+06
-+.+*5E#F
Figure 7. The structures and molecular weights of roscovitine and olomoucine (internal
standard).
16
7KH$LPRI7KLV:RUN
06
6
6+
+.
-+
0.+
0
*
0+.4+-
+
7
+6
4
8
+
6+-
0*
06+
+.
4
8
-
+6+
.
+0+
+
#
+6
7+
+
0+06
6
6+
0
7#+76
*
0-
+66
0+
<+
6
7
915:
406
6
6+
8
1+
+.
8
-
+
-
+.+
.
0-
+
6
6
66
66
46++0+
+6+0
+
+
4%'#4
06
6
17
7'
#&
7$6
66
1546
.+0
7>77
7
*
+-
.+0+.6
44
7
+
7
-
67
7
4.
.+0-+
&
.+
7.+
.0
+-
40
+
+
4>0
+.++4
->+.4
.
7
4+
+
+06
6
6006
9>:44
+
+
7
-
+06
06+
6006
4
+49P#!:
4+
++-
7++6
++
-
4
06
+66+*
.+4
+
..
+
+.
*
+-
4
.
4
4
7+
+
0+
.
*
7
4
.
+-
-
+
+
+7
44
-
4
8+0+76
006
+0
150
<+
4
6
.+0
4
0
67+.+-
*+
-
-
++
+-
4.
4<P
+
+
.++4
-<P+.
4
7+
-
4
<+
*
6
0
0+
..
-+.
+
+
+
7
6-
.+
<
<+
+.6006
0
67+.+-
4
.+-+!
<+
.
<+
..
+
+.
+-
4
.+
4
*+0
+
4
715
+
4
.
*
+
40
6+
+.6+
6
6006
6
7
+.6
++
7$4
!&
#"
*++60=
+
.+
+0
60
..
7
+
4
0
*
4
6
0+
+.+-
+06++
+0
+.
4
7++
+06++
0+
+.
+
++
B
7++
7+.
+
-
4
0<
+-
4
.++60=+
+.
<+
6+
18
7KH6RUEHQW
66
-
0
6
+
4
-
46#
-
4
(
$!2
7
6006
0-
6+
#-+
4
+
*+
6
-
7
6C+.
06
4.
96CQ":
7!H
.+0
6C
6+
7
*
4
6
+.+-
4
-++
#
<
7
+6+-
+
4
+
+-
+
7+
7+
#
<
7
+
#6+.
+
7+647
.+
<+
+.
.66
..
9//$
/!$:
+<
6+
#
-
=
6+0
91 D3:4
7
B7
$
*
+-
6
4
7
=
+.P0
6+0
6
4
%P0E!F
/4
+4
+6+-
+
6
+
7+.
-+
4
0-
+.
-+
-+
.
+.
6
+.-+
.+
+6+-
-+
-+
.
+
6
..
+.
+-
+
+
.
+.
=
4+
&
+7+64
++
.+0
+
++6+-
+
+
+
+4
6+
7
-
.+0B7
$..
9//$
/!$:6+
7
06
+
6+0
91 D3:B
+
4
7+.
-+
.
*
7
+
4+-
4
-
/4
+-
0
*6+---
7
4
7
6+
4
0
6+
7
600
19
60
Recovery (%)
50
40
30
20
10
0
ENV+
66
-
-
=
6+
4=
+-
0
*+-
+
796R!:
-7
+
6C
7
*
60
+
+
+-
++
7+
<
7
-
++
+
+
#6+
+
2
6C+.
06
0<4+4
7
+
4
6+
7
+-
0
4
7
7
4
+-
+
6+
.
+
7+6
.
+.
+-
0
0
+
+
*+-
+
4
0
-
7
+
+
476C#
96CQ!!:
*+
6-
+
0
#+
9
"":
0+
+.+-
4+60=
+
+
0+
+.06
4
7+
+
+
-
.+0B7
%966
:
!966
:
7
0+
+.07+-
0
+
4
+4
4!07*46+--
+
..
+6+
6
+.
+-
+4
07+.6
7-
4
+
*
+
.++-
7
+0
+.
+
+
4
.+
+6+
+.
*
0
0+
+-
4
6-
+
9QH:4+-
4!074
>
06
4
<
B7
%
!*0+
+.+-
4-
.++
+
7
+.#
+.
B+7
+
+
0+
+.+-
+-
20
80
Ropivacaine
PPX
3-OH-ropivacaine
Recovery (%)
60
Internal Standard
40
20
0
2 mg
1 mg
0.5 mg
Figure 9. Effect of amount of sorbent, C2, on the recovery of ropivacaine and its
metabolites PPX and 3-OH-ropivacaine compared to direct injection of pure standard
solutions.
Ropivacaine
PPX
3-OH-ropivacaine
Internal Standard
80%
Recovery
60%
40%
20%
0%
0.5 mg
1 mg
2 mg
21
7$4$4,!
5!
#
*
66+
+.
4
7+
156+
+
0+
4
+06+
.+0
+-
4++
7
0
+
-+
4
-
++
.+0
6006
-
+
+
+
#6+
+
-+
6C
+
+
+.+7
+
4
..
+
4
76
.+0
66
4
+
7..
+
+
+.+7
+
4
++60=
4
7+
*
+0
+.
4
7+
4
>
-
.+0B7
!!
7+
+
+.+7
+
4
7++
+
*
+
.+
+-
+-
4-
/4
+
60+6+-*
+.!H0
+
+
-
-+!H+06
+4
+
Relative response
0,9
0,8
r1
:1
:8
10
%
M
eO
H/
AC
N/
W
ate
AC
N
20
%
H
eO
M
eO
W
at
er
10
%
0,7
66
++
+.
460
++
+
*+6
++7
+
+
++.
6C+
7+.
4
7++
4
+
+
+.+7
+
4
7++
+46C
0
6+
7
+
4
+-
0
4
+
6
,..
0<
+.
4
0
++
7!H.+04
4
7
++
*
+4
0+
7
9R:4
+
-
.
7
+
4+-
4
7!>4
+
7!H
.+04
7++
22
7KH(OXWLRQ6ROYHQW
*
+
+
+-
+
4-
+6
7
.+0
+-
0
00+0
.
+
-
+
+6+-
+
+
+
#6++
4+-
+7+6
.+
-
+
+-
B
4
+
<
7
+
6C+.
+
+
+-
6C
-+
6
+.
7
.+
+
+
66
7
-
-
=+
+.
+-
0
+
7++
47+
7C+4
-
1##4
+6+
4
+
-
+.
6+-.++
+
0
+
.
47
4
7
+
+
EF
66
4
-
/4
+-
0
-
+6+-.+
-
4
7
6
7-
4
++
+
A
+4
6+--
+
.+
+
66
60
+
0
04+
+
+
+
4
+6+-*0
+
0
0
-+
4
0*+
7
+
6-
+.-
7-++6+-
+
.+
4
-
.+0B7
!++60=
+
..
0<
+.4
0
++
7H00+
0+<
4
+
+
6
7
+
+
+.00+
0+<
+
+
+.+6
+
+
+.
0
+
B7
!
6-
+
9QH:4+-
4
0
+K4
%9K:+
7H00+
0+<
4
*
+
+
4
-+66
23
80%
C8
C2
Recovery
60%
40%
20%
0%
M eOH/ Wat er 8:2
M eOH/ Wat er 9:1(v/ v)
(v/ v) (0.25%NH4OH)
(0.25%NH4OH)
M eOH/Water 95:5
(v/v) (0.25%NH4OH)
7$7 %
?
+.
0+
+.+0
0
#+
*
..
6
+
0
.+
7+6+
6+6
+.
66-
7
06+
+.
0
+4+
#+
..
6
+
+.
0
+*
0
#+
-
6
.+0
+.
0
+4-
E"F
66
#+
4
-
G
7
+
+
.
7
+
+
9
:-
*+
0
#
+
+-
44
-
4
<+
-
+
"!
76+
H#+
4+-
.
+
-
++
4+-
+
7+A+
#
+
7
7.+0!+H6.++0
0E"F
7$8(
!"#
,!!)
#
!
,
66
6+-
66
69>:6
40
-
0+
++-
+
+
4%'#4
6
4
.+06
7
*
%'#4
6
4
6
6
06
4
+
0.+.
-/##
4%'#6
+-
4+0
24
5++6+0
0+
++-
0
.+7#+76
+
#
51-
=
-O
EFB
7+6
..
66+
.+
.-+
+.0+
+6
6
B+
<06
C
EF
6++7.
7.+
.-+
+.
6+-
666
6
+
+6-=
+-
67
!00
7+-
.+0
6
+.66
6
+
+
66
6
4
0+
+46
6
6+0
4
+
0-+
+
64+4
E'F
6++7.
7+.-
0+
++
+
4+.
0+66
6*
66+40
4+
64
.
6
4+0+.
.
+.
6
+
+-+
0
+4
+6
06
+
6
7
.+
.-+
+.6++6+0
=
0+
+6+0
+
4+.6+6+6
66
6
7KH3UHSDUDWLRQRI3RURXV3RO\PHU0RQROLWKV
*
66
64
.
-6+
+
7+.-+$009'#(
>:46+0
=+
0<
+
7;9H:1;,9!H:
&9"H:& 9!4H4
6
+0+
+0
:!#+
+9"H:
+
<
+9"H:
*
66
64
6
6+0
=+
66
*
6+0
=+
4+4
+6+
..+'0
4
6
+.
6+4
+
D06+.!0
.+0
4
6
6
+.0+
D06.
+06
+
+.6+0
=+
64
0+
6
0++6
.+---
4
4
+
+
0+
6++7
+
+
+06+
0
7
0+
+&
.+
6
4
4
4
+
+
B+6++7607
+.
0+
++-
-+"00+
706
.+0
644=+-
4
++74
+
4
0+.
+7
6\QWKHVLVRI3RO\*0$(*'0$%0$0RQROLWKVIRU3LSHWWH7LSV
*
6++0+
+4
=
6+-
66
6-
D#7
6+0
=+
B7
!"66++76
07
+.
0+
+
66
6
7+06
.
7
+.
6+0
+
-
+7
.
..
++
-
4
6+0
0<
6
-
,
6
66+
+.
76
96+-:
0+
+
+6++.
6*
..
-
7+.
0+
++
6-
-
25
E'F
C+4
4
6
.+0
+.
<6
0
44
..
+
0
+
<0
0
+.
0+
++
-
2
+
4
++
0
9
"0
:4
0+
+06++.
-
5+-
4
+
+76+0
+.
0+
+*+
+
-
6+0
+
4+.
-
0
-
B
4
+
06+
+6
6
D-+<+
8
+
Figure 13. A photographic image of UV-polymerized monolith inside a disposable micro
pipette tip. The polymerization mixture contained GMA 20%, EGDMA 15.5%, BMA 3.5%,
AIBN 1% (with respect to monomers), cyclohexanol 30% and 1-dodecanol 30%.
Polymerization was allowed to proceed for 85 minutes using 254 nm light.
7$8$:"#
*+
6
.+0
+.
0+
+6++
0
60
4
4
0+
-
*
0
6
6
%'66
64
-+-+5
+
56
+955# #:+-
.+06+,
7
9/ :
B7
!*
6
60+4
06
9!P:.+0%'#4
6
4
4
6-
+-+2
06
4
6
+7
0+
+6+0
4
+-
+*
+6
4
4
+
44
9!P:+
0+
6+
+
.
B
4
40
+9!P:+
/0+-
6
+%'#4
6
.+.
-/##
76+
7+.
06
.+06+-
.
%'#4
6
46
.+0
4+0
S
6
+.6+.
6+
47
26
Figure 14. Packed 96-tips with monolithic methacrylate polymer.
6HOHFWLYLW\
*
0
+
.
+
#
.
4
+7
+
-
7+
+.
B7
!
!&+4
6
+0+70+.-
0
60
0
606
4
++
++0+
9:+
7+
+0+70
/##
+.++
0
60
70+
+66
6
+
.
7+06+
4
0
+
0
+06+
*
7++
.+
66+
+.
0+
++
7606
6
6+
0
+
+.
++
27
041005024
100
Blank plasma
0
1.00
2.00
3.00
4.00
5.00
Time
7.00
8.00
MRM of 2 Channels ES+
299 > 91
2.96e5
6.00
041005086
4.87
100
IS
Blank plasma
0
1.00
2.00
3.00
4.00
5.00
6.00
7.00
8.00
Time
Figure 15. Chromatograms of (A) blank plasma and plasma spiked with 125 nM
roscovitine and (B) blank plasma and plasma spiked with olomoucine (I.S.).
Chromatographic conditions: column Zorbax 50 x 2.1 mm I.D., SB-C8, 3,5 m connected
to a guard column, an Optiguard 10 x 1 mm I.D., C8; mobile phase (A) 0.1 % formic acid in
ACN-Water (10:90, v/v), (B) 0.1% formic acid in ACN-Water (80-20, v/v); linear gradient
0% B for 1 min, 0-80% B in 4 min, 80% B in 1 min; flow rate 150 L/min.
28
&RQFOXVLRQV
+
<+
6
7
915:+
#
4/##
<
06
6
6+
8
44
0+
.+
0
+
+.+
0
6006
/+
+
+06
154.+0
06
+++
+
0
+
<
66+
+6006
0
67+.+-
+-
.+-+!
<+
-
.+
<+
..
+
4
B
4+4
15
6+
-
8
006
+0
+
0
+4+
+0
+-
4..
+-
0
+
6+-
66
64
6
467+.0
-
6++6+0
0+
+06
+-
6
%'#
64
+
+
4%'#4
6
A++
0
60
4
06
4
0+
-
7
0%'
06
4
6
6
.+
4+0
*
6
4++-
+
6
+60
+.
0+0
0
.+7
06
+76
6+
+
29
30
5HIHUHQFHV
E!F
EF
E"F
EF
EF
E'F
E(F
E$F
E%F
E!F
E!!F
E!F
E!"F
E!F
E!F
E!'F
E!(F
E!$F
E!%F
+
$'9!%%%:"
X$$9:"
JC
+
1&
4
;A
(9!%%$:'
/B5++
!
3 !! J
54=
91+:1
0
06""
C&B
+
;2+
"9!%!:!!'
1*0
!"&4 5 !
2
4Y+!%%$
C+!9":"
C+ !9:'
1*0
!!%9:!$
2J
C+A
4;J
J+
7($$
9!%%%:!!(
2J
C+2
170+
J5B
A
4
;J
J+
7(''9:"(
/J
,;+
B
(%%9:%
C
7
B&
(%9":""(
C+05+
1
Z
-[*;
-+
(%9":!($
+
A=
J#D
$!9:!!
,,
B
7
// 6!9:$
A1
J54=
'%9!%%(:"!
A;&
J54=
7#9!%$%:!(%
31
EF
E!F
EF
E"F
EF
EF
E'F
E(F
E$F
E%F
E"F
E"!F
E"F
E""F
E"F
E"F
E"'F
E"(F
32
/J54=
'9!%%:!
J54=
91+: !" 4 5! 2
4Y+!%%(
J6
3 "'(9:
J6
3 "'%9!:(
1&
5
B,//0
!!9!%%%:
("(
B,&*
6
5JB
89&J:;<<=>!
-
#A
09?2
"!2?"!%!%
9":6((
-
#A
0$!9:"!(
B\
*&*
E"$F
E"%F
EF
E!F
EF
E"F
EF
EF
E'F
E(F
E$F
E%F
EF
E!F
EF
E"F
+
/ / 9!%%':%
+*0,*2+
7+
A!9:%
&+7
A;+
(#9":!(
G
&+7
?
J5/+
7JJ&+4
7
7J;,
+J5+
+<& "9!%%(:(
2B,
=
+
G
C
C
0& "9!%%(:!$
C
+4B
?
2
A
7
B
B
/5
*,
' !$9:9:((
JD
C
JJ&+4,+
#,
5
33
EF
EF
E'F
34
Sample preparation is often a bottleneck in systems for chemical analysis. The aim
of this work was to investigate and develop new techniques to address some of the
shortcomings of current sample preparation methods. The goal has been to provide
full automation, on-line coupling to detection systems, short sample preparation
times and high-throughput.
A new technique for sample preparation that can be connected on-line to liquid
chromatography (LC) and gas chromatography (GC) has been developed. Microextraction in packed syringe (MEPS) is a new solid-phase extraction (SPE) technique
that is miniaturized and can be fully automated. In MEPS approximately 1 mg of
sorbent material is inserted into a gas tight syringe (100-250 L) as a plug. Sample
preparation takes place on the packed bed. Evaluation of the technique was done
by the determination of local anaesthetics in human plasma samples using MEPS
on-line with LC and tandem mass spectrometry (MS-MS). MEPS connected to an
autosampler was fully automated and clean-up of the samples took one minute. In
addition, in the case of plasma samples the same plug of sorbent could be used for
about 100 extractions before it was discarded.
A further aim of this work was to increase sample preparation throughput. To do
that disposable pipette tips were packed with a plug of porous polymer monoliths
as sample adsorbent and were then used in connection with 96-well plates and LCMS-MS. When roscovitine in human plasma and water samples was used as model
substance, a 96-plate was handled in two minutes.